Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Southwest Research Institute (SwRI) in the US has leveraged its virtual screening software to speed-up the identification of potential treatments for coronavirus, among other infections.

The software, Rhodium, analysed two million drug compounds recently in an effort to find coronavirus drugs with efficacy and slight adverse side effects. A 3D coronavirus model was used to assess a library of compounds.

Researchers launched molecular modelling research and intend to team up with local partners, including the Texas Biomedical Research Institute, for the next phase.

During the upcoming phase, the team will identify the candidates most promising for further development.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The institute previously increased the capacity of the virtual screening tool from scanning 25,000 drug compounds per day to 250,000.

SwRI research scientist Dr Shawn Blumberg said: “This advanced processing capability is demonstrating that virtual screening can rapidly increase the pace of drug discovery, especially in pandemic situations.”

Virtual screening uses computational methods to analyse small molecules and predict the mechanism with which protein structures in infectious diseases attach to drug compounds.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact